List of Excipients in Branded Drug TRAVATAN Z

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Alcon Laboratories Inc	TRAVATAN Z	travoprost	0065-0260	BORIC ACID
Alcon Laboratories Inc	TRAVATAN Z	travoprost	0065-0260	HYDROCHLORIC ACID
Alcon Laboratories Inc	TRAVATAN Z	travoprost	0065-0260	POLYOXYL 40 CASTOR OIL
Alcon Laboratories Inc	TRAVATAN Z	travoprost	0065-0260	PROPYLENE GLYCOL
Alcon Laboratories Inc	TRAVATAN Z	travoprost	0065-0260	SODIUM HYDROXIDE

Travatan Z Excipient Strategy and Commercial Opportunities

Last updated: August 9, 2026

Travatan Z is a mature travoprost ophthalmic product differentiated primarily by its benzalkonium chloride-free preservative system, not by the active pharmaceutical ingredient. Its commercial value rests on ocular-surface tolerability, multidose convenience, and brand recognition in glaucoma treatment. The strongest future opportunities are preservative-free delivery, low-irritation formulations, combination products, and packaging technologies that preserve sterility without benzalkonium chloride.

What is the excipient strategy behind Travatan Z?

Travatan Z contains travoprost 0.004% in a multidose ophthalmic solution preserved with the SofZia system. The formulation avoids benzalkonium chloride, commonly abbreviated BAK, which is used in many ophthalmic products but has been associated with ocular-surface irritation and toxicity concerns with chronic exposure.

Travatan Z formulation composition

Component	Function in formulation
Travoprost 0.004%	Prostaglandin F2α analog; active ingredient
Boric acid	Buffering and formulation support
Propylene glycol	Solvent and tonicity contribution
Sorbitol	Tonicity adjustment and formulation stabilization
Zinc chloride	Component of the SofZia preservative system
Polyquaternium-1	Antimicrobial preservative component in the commercial formulation
Hydrochloric acid and sodium hydroxide	pH adjustment
Purified water	Vehicle

Travatan Z is supplied as a sterile ophthalmic solution in a multidose bottle. The product label identifies the formulation as BAK-free and preserved with the SofZia system.[1]

The commercial strategy is based on replacing BAK with an alternative antimicrobial system that is intended to reduce ocular-surface exposure to a widely used but controversial preservative. The excipient system must maintain sterility during repeated bottle access while remaining compatible with travoprost, the bottle, the dropper tip, and the ocular surface.

How does SofZia compare with benzalkonium chloride?

SofZia differentiates Travatan Z from conventional BAK-preserved travoprost products. The commercial distinction is clinically relevant because glaucoma patients often use topical therapy for years and may receive multiple preserved eye drops concurrently.

Attribute	SofZia formulation	BAK-preserved formulation
Primary commercial positioning	BAK-free alternative	Conventional multidose preservation
Intended benefit	Lower preservative burden on ocular surface	Established antimicrobial performance
Patient segment	Chronic users, ocular-surface disease, contact-lens-sensitive patients	Broad glaucoma population
Formulation complexity	Higher excipient and compatibility burden	Lower formulation complexity
Manufacturing cost	Potentially higher	Generally lower
Differentiation potential	High	Limited
Substitution risk	Generic products may not use the same preservative system	High generic availability

The formulation difference does not automatically establish clinical superiority for every patient. Its commercial effect is strongest in patients who experience irritation, dry eye, conjunctival inflammation, or intolerance to BAK-containing therapy.

Travatan Z’s excipient strategy also creates a regulatory and manufacturing burden. A non-BAK preservative must demonstrate antimicrobial effectiveness, product stability, container compatibility, and acceptable ocular tolerability. These requirements can raise development costs compared with a conventional BAK-preserved generic.

What commercial opportunities exist for Travatan Z excipients?

The main commercial opportunities are product extensions that preserve the BAK-free positioning while improving adherence, tolerability, or convenience.

1. Preservative-free travoprost

A preservative-free travoprost product would target patients with chronic ocular-surface disease, severe dry eye, glaucoma requiring several topical therapies, and patients who have failed BAK-preserved products.

Potential delivery formats include:

• Single-dose unit containers
• Blow-fill-seal ampoules
• Multidose preservative-free pumps
• One-way valve bottles
• Airless or mechanically protected dispensers

The commercial tradeoff is packaging cost. Unit-dose packaging reduces preservative requirements but increases material use, filling complexity, shipping volume, and patient handling. A multidose preservative-free device may offer better adherence and lower long-term packaging cost, but it requires more complex microbiological validation.

2. Low-irritation fixed-dose combinations

Travoprost could be combined with another glaucoma active ingredient in a BAK-free or preservative-free system. Relevant combination targets include:

• Travoprost plus timolol
• Travoprost plus a carbonic anhydrase inhibitor
• Travoprost plus an alpha-2 agonist

A fixed-dose combination can reduce the number of daily instillations and lower cumulative preservative exposure. The principal technical challenges are pH compatibility, solubility, chemical degradation, adsorption to packaging, and preservation across multiple active ingredients.

A commercial product would need to demonstrate that the excipient system does not compromise either active ingredient. It would also face competitive pressure from established fixed-dose glaucoma products and generic combinations.

3. Improved multidose delivery

Travatan Z uses a conventional multidose bottle. Device improvements could create a new commercial position without materially changing the active formulation.

Potential improvements include:

• Metered-dose delivery to reduce drop size
• One-handed administration
• Reduced bottle squeeze force
• Tip protection against contamination
• Dose counters
• Smart adherence monitoring
• Ergonomic packaging for elderly patients

Travoprost is used predominantly by older patients, making dexterity and administration errors commercially important. A smaller, reproducible drop may reduce product waste and excess ocular exposure.

4. Contact-lens and ocular-surface positioning

A BAK-free formulation can be positioned for patients who use contact lenses or have ocular-surface sensitivity. The product still requires appropriate administration instructions because ophthalmic products may need to be removed before instillation and reinserted after a defined interval.

This opportunity is more credible as a targeted adherence and tolerability strategy than as a broad clinical superiority claim. Promotional claims would require support from controlled clinical evidence and applicable FDA advertising standards.

5. Pediatric and specialty formulations

Travoprost is primarily used in adults, but a lower-irritation formulation could support specialty development in selected pediatric glaucoma populations. Pediatric development would require separate safety, dosing, administration, and packaging work. The commercial market is smaller than the adult glaucoma market, but physician demand for tolerable chronic therapy can support niche pricing.

6. Contract development and licensing

The excipient and delivery technology can have value independently of Travatan Z. Companies with a validated BAK-free preservative system, preservative-free multidose device, or low-volume ophthalmic dispenser could license those technologies to:

• Generic ophthalmic manufacturers
• Specialty pharmaceutical companies
• Branded glaucoma companies
• Developers of chronic ocular-surface treatments
• Manufacturers of fixed-dose glaucoma combinations

The most attractive licensing assets are platform technologies that support multiple active ingredients rather than a formulation limited to travoprost.

What patents protect Travatan Z and its formulation?

Travatan Z is a small-molecule ophthalmic drug, so it does not have biosimilar exclusivity issues. Its historical protection would have included travoprost composition, ophthalmic formulation, therapeutic use, and potentially preservative or delivery-system claims.

The relevant protection categories are:

Protection category	Relevance to Travatan Z
Travoprost composition patents	Historically protected the active molecule
Ophthalmic formulation patents	May cover concentration, solvents, buffers, or stabilizers
Preservative-system patents	May cover BAK-free preservation or SofZia-related combinations
Method-of-use patents	May cover treatment of elevated intraocular pressure or glaucoma
Container and dispensing patents	May cover multidose delivery and contamination control
Manufacturing patents	May cover sterile filling, mixing, or stability processes

Public regulatory records identify Travatan Z as NDA 021994. The FDA-approved product is manufactured and marketed by Alcon Pharmaceuticals Ltd. The original travoprost product, Travatan, was approved under a separate NDA.[1,2]

The commercial importance of historical formulation patents has declined because the principal product is mature and generic travoprost products are available. The remaining value is more likely to reside in device claims, specific preservative-free systems, improved formulations, and differentiated combinations than in broad travoprost composition claims.

What is the Orange Book status of Travatan Z?

The FDA Orange Book is the controlling source for current listed patents, expiration dates, therapeutic equivalence evaluations, and exclusivity information.[3] Travatan Z’s current commercial risk should be assessed against the active Orange Book listing for NDA 021994 rather than against historical patent records or third-party databases.

For a mature product such as Travatan Z, three distinctions are important:

1. A patent may have expired even if the product remains branded.
2. A formulation difference may not be protected by a currently enforceable patent.
3. A generic travoprost product may be therapeutically equivalent while using different excipients.

The Orange Book does not establish freedom to operate for all formulation, device, manufacturing, or foreign-market claims. A separate patent search is required for those categories.

When does Travatan Z lose exclusivity?

Travatan Z’s regulatory exclusivity and patent protection are separate issues. The product was approved in 2006, and its original commercial protection has largely matured. Generic travoprost ophthalmic products have entered the U.S. market, creating substantial price and formulary pressure.

Milestone	Strategic significance
2006 FDA approval of Travatan Z	Established the BAK-free travoprost product
Patent term through the 2010s and early 2020s	Supported historical brand protection
Generic travoprost approvals	Increased substitution and reduced active-ingredient exclusivity
Current mature-market phase	Value shifts to formulation, device, brand, and channel differentiation

The exact date on which a particular patent expires depends on the patent number, terminal disclaimers, patent-term adjustment, and any regulatory extension. Current patent conclusions should use the FDA Orange Book and USPTO records.[3,4]

Travatan Z no longer has the commercial profile of a product protected primarily by unchallenged active-ingredient exclusivity. Its opportunity is lifecycle management.

Which companies are challenging Travatan Z?

Generic manufacturers have challenged the broader travoprost market through abbreviated new drug applications rather than through direct competition with every excipient element of the branded product.

Potential competitive groups include:

• Large generic manufacturers with ophthalmic manufacturing capacity
• Specialty generic companies focused on sterile eye drops
• Contract manufacturers supplying private-label ophthalmic products
• Developers of preservative-free prostaglandin analogs
• Companies commercializing fixed-dose glaucoma combinations

A generic applicant may seek approval for travoprost 0.004% with a BAK-containing formulation, a different preservative system, or a preservative-free presentation. Therapeutic equivalence and substitutability depend on FDA approval and the specific product designation, not simply on matching the active ingredient.

What Paragraph IV challenges affect Travatan Z?

A Paragraph IV certification alleges that a listed patent is invalid, unenforceable, or would not be infringed by the proposed generic. For Travatan Z, the most important issue is whether current Orange Book-listed patents remain relevant to an ANDA applicant.

The practical analysis requires four steps:

1. Identify each patent listed against NDA 021994.
2. Review the expiration date and any pediatric or patent-term adjustment.
3. Determine whether the ANDA product uses the claimed formulation or device.
4. Review any litigation, settlement, or 30-month-stay history.

Public FDA records and federal court dockets should be used to confirm Paragraph IV notices, patent litigation, and settlement terms. No current settlement terms should be inferred from the existence of generic travoprost products alone.

What formulation patents could create new commercial value?

Future formulation patents are most likely to focus on measurable technical features rather than a general BAK-free claim.

Potential claim areas include:

• Specific ratios of boric acid, propylene glycol, sorbitol, and zinc salts
• Preservative concentrations that maintain antimicrobial activity with reduced irritation
• Travoprost stabilization against hydrolysis or oxidation
• Low-volume or controlled-size drops
• Preservative-free multidose delivery
• Container closure systems that limit microbial ingress
• Compatibility between the formulation and low-adsorption polymers
• Improved bottle designs that reduce residual volume
• Formulations optimized for coadministration with other glaucoma drugs

A strong formulation patent should link the composition to unexpected stability, preservative effectiveness, tolerability, or delivery performance. A simple substitution of one conventional excipient for another may face obviousness challenges.

How strong is the Travatan Z patent estate?

The historical estate was stronger when travoprost composition and branded formulation patents blocked direct generic competition. Its current strength is lower because the active ingredient is mature, generic alternatives exist, and excipient differences can support non-infringing products.

Estate element	Current strategic strength
Broad travoprost composition claims	Low after maturity and expiration
BAK-free formulation claims	Moderate if claims are narrow and technically supported
SofZia-specific claims	Moderate, depending on live claim scope
Preservative-free device claims	Potentially strong for differentiated products
Method-of-use claims	Limited against generic substitution in many cases
Manufacturing claims	Relevant for supply-chain control, less powerful against finished-product competition
Brand and physician familiarity	Commercially meaningful but not patent protection

The most defensible new intellectual property would combine a specific excipient profile with a validated performance advantage and a proprietary container system.

What FDA regulatory status applies to Travatan Z and its excipients?

Travatan Z is an FDA-approved ophthalmic solution for reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.[1] Its excipients are regulated as part of the finished drug product rather than as independent over-the-counter ingredients.

A new Travatan Z lifecycle product could use several pathways:

Product concept	Likely regulatory pathway
Same active, same strength, different excipients	ANDA may be difficult if formulation differences affect equivalence
Generic travoprost with alternative preservative	ANDA with product-specific bioequivalence and quality requirements
New preservative-free multidose device	505(b)(2) or ANDA, depending on formulation and device differences
New fixed-dose combination	505(b)(2), NDA, or combination-product pathway
New patient population or dosing regimen	505(b)(2) or NDA
New delivery technology	505(b)(2), NDA, or device combination pathway

Ophthalmic products require sterile manufacturing, container-closure integrity, microbial limits, preservative effectiveness, extractables and leachables assessment, particulate control, and stability testing. The FDA also expects ophthalmic products to comply with applicable current good manufacturing practice requirements and relevant pharmacopoeial standards.[5,6]

What manufacturing and IP barriers affect commercial entry?

The principal barriers are technical rather than ingredient availability.

Sterile manufacturing

A manufacturer must control bioburden, endotoxin, particulate matter, fill accuracy, and container closure. A BAK-free or preservative-free product has less tolerance for microbial-control failures.

Preservative effectiveness

The alternative preservative system must remain effective throughout in-use shelf life. Testing must account for repeated bottle opening, patient handling, container geometry, and the formulation’s pH and ionic strength.

Container compatibility

Travoprost and excipients may interact with bottle polymers, elastomers, adhesives, or labels. Adsorption can reduce delivered dose. Leachables can affect safety and stability.

Drop-size control

An oversized drop increases waste and may increase systemic absorption through nasolacrimal drainage. A controlled-dose dispenser can improve economics but may require device validation and additional regulatory work.

Supply-chain complexity

Boric acid, propylene glycol, sorbitol, zinc chloride, preservative components, and ophthalmic-grade packaging must be controlled for quality and supply continuity. The commercial value of the formulation depends on reliable sterile fill-finish capacity.

How does Travatan Z compare with competing glaucoma products?

Product category	Differentiation	Commercial threat to Travatan Z
Generic travoprost	Lower price; variable preservative systems	High
Bimatoprost	Strong efficacy positioning and broad generic availability	High
Latanoprost	Extensive use and low-cost generic supply	High
Tafluprost	Preservative-free positioning in some markets	Moderate to high
Fixed-dose combinations	Fewer daily drops and improved adherence	High
Sustained-release implants	Reduced dosing frequency	Emerging
Laser and surgical therapies	Reduced dependence on topical drugs	Moderate

Travatan Z is best positioned against BAK-preserved topical therapies and in patients for whom ocular-surface tolerability affects persistence. It faces greater pressure in formularies that prioritize low-cost generic latanoprost or travoprost.

What revenue exposure exists for Travatan Z?

Alcon reports ophthalmic pharmaceutical sales at portfolio or category level rather than providing a consistently separate public revenue line for Travatan Z. Product-level revenue exposure is therefore best assessed through prescription volume, payer coverage, generic substitution, channel inventory, and regional availability rather than a disclosed standalone figure.[7]

The principal revenue risks are:

• Generic substitution for travoprost
• Formulary preference for latanoprost
• Price compression in mature glaucoma products
• Declining use of preserved eye drops in favor of preservative-free alternatives
• Competition from fixed-dose combinations
• Greater adoption of laser or sustained-release therapies

The principal revenue opportunities are:

• Premium pricing for BAK-free therapy
• Higher persistence among ocular-surface-sensitive patients
• Preservative-free lifecycle extensions
• Device-enabled adherence products
• Regional licensing of SofZia-like technology
• Fixed-dose combinations using a low-irritation excipient system

What licensing deals and partnerships are relevant?

Travatan Z is associated with Alcon’s ophthalmic pharmaceutical portfolio following the separation of Alcon from Novartis. Public company disclosures identify Alcon as the commercial owner of the ophthalmic franchise, but do not provide a current product-level licensing arrangement for Travatan Z.[7,8]

The most commercially relevant partnership opportunities are technology transactions involving:

• Non-BAK preservative systems
• Preservative-free multidose dispensers
• Sterile ophthalmic contract manufacturing
• Fixed-dose combination development
• Regional commercialization rights
• Generic or authorized-generic supply

A licensing transaction would be more defensible when it includes issued or pending formulation and device claims, validated stability data, and manufacturing scale-up evidence.

What generic launch scenarios exist for Travatan Z?

Scenario 1: Low-cost BAK-preserved generic

This is the most direct price competitor. It can capture patients and formularies that prioritize active-ingredient equivalence and cost over preservative profile.

Scenario 2: Generic with an alternative preservative

This product competes more directly with Travatan Z’s formulation positioning. Its success depends on tolerability data, physician awareness, reimbursement, and therapeutic-equivalence status.

Scenario 3: Preservative-free generic

This product could compete for the same ocular-surface-sensitive population but may carry higher packaging and manufacturing costs.

Scenario 4: Fixed-dose travoprost combination

This product competes through reduced administration burden rather than through excipient similarity. It can take share from separate travoprost and timolol prescriptions.

Scenario 5: Device-led differentiated product

A controlled-dose or adherence-enabled product could maintain premium pricing despite active-ingredient maturity.

What is the geographic coverage of the Travatan Z opportunity?

The BAK-free positioning has broad relevance, but regulatory and commercial value varies by market.

Region	Opportunity
United States	Mature generic market; strongest opportunity in differentiated devices and preservative-free products
Europe	Greater emphasis on ocular-surface tolerability and preservative reduction; country-level reimbursement varies
Japan	High value in premium ophthalmic products, but local regulatory and commercial requirements apply
China	Growing glaucoma market; local registration, pricing, and manufacturing partnerships are important
Emerging markets	Volume opportunity, but low-cost generics may limit premium pricing

Patent expiry and regulatory exclusivity must be evaluated separately in each jurisdiction. A U.S. formulation strategy does not establish protection in Europe, Japan, China, or other markets.

Key Takeaways

• Travatan Z’s central differentiation is a BAK-free SofZia-preserved ophthalmic formulation.
• The formulation uses boric acid, propylene glycol, sorbitol, zinc chloride, and other excipients to support preservation, tonicity, pH control, and product stability.
• The strongest commercial opportunities are preservative-free travoprost, improved multidose devices, fixed-dose combinations, and low-irritation glaucoma products.
• Generic travoprost creates substantial price and substitution pressure.
• The active-ingredient patent estate is mature; future value is more likely to come from formulation, device, packaging, and combination-product claims.
• Travatan Z has no biosimilar issue because travoprost is a small molecule.
• Product-level Travatan Z revenue is not separately disclosed in Alcon’s public reporting.
• Current Orange Book listings, USPTO records, and federal court dockets control the assessment of live patents, Paragraph IV challenges, and litigation exposure.

FAQs

Is Travatan Z preservative-free?

No. Travatan Z is BAK-free but uses the SofZia preservative system in a multidose bottle.

Which excipient makes Travatan Z different from standard travoprost?

The principal differentiation is the non-BAK preservation system, supported by boric acid, propylene glycol, sorbitol, zinc chloride, and preservative components identified in the product labeling.

Can a generic travoprost product substitute automatically for Travatan Z?

Substitution depends on the FDA therapeutic-equivalence designation, state pharmacy law, payer policy, and the specific generic formulation. Matching travoprost strength alone does not mean the products have identical excipients.

Is a preservative-free travoprost product commercially attractive?

Yes. It could target chronic glaucoma patients with dry eye, ocular-surface disease, or intolerance to preserved therapy. The main constraints are packaging cost, sterility assurance, and regulatory validation.

Does Travatan Z have biosimilar competition?

No. Travatan Z contains travoprost, a small-molecule active ingredient. Competition proceeds through generic drug pathways rather than biosimilar regulation.

References

1. U.S. Food and Drug Administration. (2024). Travatan Z (travoprost ophthalmic solution) prescribing information. DailyMed.
2. U.S. Food and Drug Administration. (2006). NDA 021994: Travatan Z. Drugs@FDA.
3. U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: Orange Book.
4. United States Patent and Trademark Office. (2025). Patent Center and patent term adjustment records.
5. U.S. Food and Drug Administration. (2008). Sterile drug products produced by aseptic processing: Current good manufacturing practice guidance for industry.
6. United States Pharmacopeia. (2024). General chapters <51>, <71>, and ophthalmic product standards. United States Pharmacopeial Convention.
7. Alcon Inc. (2024). Annual report for the year ended December 31, 2024.
8. Novartis AG. (2019). Completion of the Alcon spin-off and distribution to shareholders.